About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker TAK · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058 · Psoriatic Arthritis
Zasocitinib
TAK
Takeda
Phase 3Recruiting1,182Dec 18, 2029Registry ↗
Nov 12, 2026A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
NCT06677892 · Cytomegalovirus (CMV)
No Intervention
TAK
Takeda
—Completed
was active, not recruiting
66Aug 1, 2026Registry ↗
Nov 12, 2026A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483 · Psoriatic Arthritis
Zasocitinib, Active Comparator
TAK
Takeda
Phase 3Active, not recruiting
was recruiting
1,583May 18, 2027Registry ↗
Nov 12, 2026Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Li…
NCT06165341 · Alpha1-Antitrypsin Deficiency
Fazirsiran Injection, Placebo
TAK
Takeda
Phase 3Recruiting50Aug 26, 2028Registry ↗
Nov 12, 2026An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help Peo…
NCT05899673 · Alpha1-Antitrypsin Deficiency
Fazirsiran Injection
TAK
Takeda
Phase 3Active, not recruiting200May 2, 2033Registry ↗
Nov 12, 2026A Survey of Lanadelumab in Participants With Hereditary Angioedema
NCT05397431 · Hereditary Angioedema (HAE)
Lanadelumab
TAK
Takeda
—Completed
was active, not recruiting
157Oct 27, 2026Registry ↗
Nov 12, 2026A Survey of Darvadstrocel in People With Crohn's Disease
NCT05113095 · Crohn's Disease
Darvadstrocel
TAK
Takeda
—Recruiting275Dec 31, 2029Registry ↗
Nov 10, 2026Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell A…
NCT04530123 · Celiac Disease
Placebo, TAK-101
TAK
Takeda
Phase 2Completed102Dec 9, 2025Registry ↗
Nov 10, 2026A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants…
NCT02979522 · Hodgkin Disease
Brentuximab vedotin, Doxorubicin
TAK
Takeda
Phase 1/2Active, not recruiting59May 5, 2020Registry ↗
Nov 9, 2026A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of S…
NCT07263685 · Hereditary Angioedema (HAE)
No intervention
TAK
Takeda
—Completed
was recruiting
47Nov 3, 2026Registry ↗
Nov 9, 2026A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
NCT06550882 · Acquired Hemophilia A
OBIZUR
TAK
Takeda
—Recruiting11Dec 31, 2028Registry ↗
Nov 6, 2026A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ru…
NCT07623161 · Myelofibrosis, Anemia
Placebo, Elritercept
TAK
Takeda
Phase 3Recruiting324Dec 7, 2029Registry ↗
Nov 6, 2026A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transpl…
NCT07613359 · Antibody-Mediated Rejection (AMR)
Mezagitamab, Placebo
TAK
Takeda
Phase 2Recruiting
was not yet recruiting
36Jan 15, 2029Registry ↗
Nov 6, 2026A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodys…
NCT07422480 · Myelodysplastic Syndrome, Anemia
Elritercept, Epoetin Alfa
TAK
Takeda
Phase 3Recruiting300Apr 30, 2029Registry ↗
Nov 6, 2026A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated…
NCT07353099 · Thrombotic Thrombocytopenic Purpura (TTP)
No Intervention
TAK
Takeda
—Recruiting50Apr 1, 2030Registry ↗
Nov 6, 2026A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantat…
NCT06555432 · Cytomegalovirus (CMV)
LIVTENCITY
TAK
Takeda
—Recruiting168Oct 1, 2028Registry ↗
Nov 6, 2026A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysp…
NCT06499285 · Myelodysplastic Syndromes
Elritercept, Placebo
TAK
Takeda
Phase 3Recruiting225Sep 15, 2028Registry ↗
Nov 5, 2026A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678 · Idiopathic Hypersomnia, Narcolepsy Type 1
TAK-360, Placebo
TAK
Takeda
Phase 2/3Recruiting500Jun 15, 2031Registry ↗
Nov 4, 2026A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
NCT07752108 · Palmoplantar Psoriasis
Zasocitinib
TAK
Takeda
Phase 3Not yet recruiting40May 30, 2027Registry ↗
Nov 4, 2026A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263 · Hidradenitis Suppurativa
Zasocitinib (Dose A), Placebo
TAK
Takeda
Phase 2Active, not recruiting
was recruiting
91Feb 5, 2027Registry ↗
Nov 4, 2026A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827 · Kidney Disease
Mezagitamab, Placebo
TAK
Takeda
Phase 3Recruiting347Sep 7, 2028Registry ↗
Nov 4, 2026A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235 · Immune Thrombocytopenic Purpura (ITP)
Mezagitamab, Placebo
TAK
Takeda
Phase 3Recruiting171Mar 16, 2028Registry ↗
Nov 4, 2026A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psori…
NCT06323356 · Generalized Pustular Psoriasis, Erythrodermic Psoriasis
TAK-279
TAK
Takeda
Phase 3Completed18Oct 17, 2025Registry ↗
Nov 3, 2026A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283 · Nonsegmental Vitiligo
Zasocitinib, Placebo
TAK
Takeda
Phase 2Active, not recruiting
was recruiting
207Mar 26, 2027Registry ↗
Nov 3, 2026A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (…
TAK-411
TAK
Takeda
Phase 2Recruiting36Dec 2, 2027Registry ↗
Nov 2, 2026A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301 · IO Resistant Squamous and Nonsquamous NSCLC
TAK-928, Control Arm
TAK
Takeda
Phase 3Recruiting1,200Nov 1, 2028Registry ↗
Nov 2, 2026A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participant…
NCT06233461 · Crohn's Disease
TAK-279, Placebo
TAK
Takeda
Phase 2Recruiting268Feb 17, 2027Registry ↗
Nov 2, 2026A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897 · Crohn's Disease
Vedolizumab IV, Placebo
TAK
Takeda
Phase 3Recruiting408Mar 8, 2030Registry ↗
Oct 30, 2026A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
TAK-861, Placebo
TAK
Takeda
Phase 3Active, not recruiting98Dec 17, 2026Registry ↗
Oct 30, 2026Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
NCT07299097 · Narcolepsy Type 1, Narcolepsy Type 2
No intervention
TAK
Takeda
—Active, not recruiting402Dec 31, 2026Registry ↗
Oct 30, 2026A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318 · Immune Thrombocytopenic Purpura (ITP)
Mezagitamab
TAK
Takeda
Phase 3Recruiting150Jul 29, 2029Registry ↗
Oct 30, 2026A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
NCT03807778 · Non-Small Cell Lung Cancer
Mobocertinib
TAK
Takeda
Phase 1Active, not recruiting53Nov 8, 2021Registry ↗
Oct 29, 2026A Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada
NCT07903220 · Narcolepsy Type 1
No intervention
TAK
Takeda
—Not yet recruiting400Sep 30, 2027Registry ↗
Oct 29, 2026A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
NCT07204314 · Major Depressive Disorder
Vortioxetine tablets, Placebo tablets
TAK
Takeda
Phase 3Recruiting180Sep 30, 2029Registry ↗
Oct 28, 2026A Study of TAK-505 in Adults With Solid Tumors
NCT07436728 · Malignant Solid Tumors
TAK-505
TAK
Takeda
Phase 1/2Recruiting151Aug 18, 2030Registry ↗
Oct 28, 2026A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
NCT07319845 · Myelodysplastic Syndromes
TAK-226
TAK
Takeda
Phase 2Recruiting42Jun 26, 2028Registry ↗
Oct 28, 2026A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Commun…
NCT06581328 · Ulcerative Colitis, Crohn's Disease
Vedolizumab IV, Vedolizumab SC
TAK
Takeda
Phase 4Recruiting200May 1, 2027Registry ↗
Oct 28, 2026A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116 · Carcinoma, Non-Small-Cell Lung
TAK-788
TAK
Takeda
Phase 1/2Completed324Sep 29, 2026Registry ↗
Oct 27, 2026A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
NCT07871721 · Psoriatic Arthritis
Placebo, Zasocitinib
TAK
Takeda
Phase 3Not yet recruiting644Apr 18, 2030Registry ↗
Oct 26, 2026A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128 · Ulcerative Colitis
Vedolizumab, Tofacitinib
TAK
Takeda
Phase 4Active, not recruiting60Jul 9, 2027Registry ↗
Oct 23, 2026A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults Wit…
NCT06045754 · Crohn's Disease
Vedolizumab, Adalimumab
TAK
Takeda
Phase 4Active, not recruiting50Jun 28, 2027Registry ↗
Oct 23, 2026TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (…
NCT04129502 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK-788, Pemetrexed
TAK
Takeda
Phase 3Completed354Sep 22, 2026Registry ↗
Oct 22, 2026A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults Wi…
NCT04420884 · Solid Neoplasms
Dazostinag, Pembrolizumab
TAK
Takeda
Phase 1/2Completed248Mar 30, 2026Registry ↗
Oct 20, 2026A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Pur…
NCT07429942 · Thrombotic Thrombocytopenic Purpura (TTP)
No Intervention
TAK
Takeda
—Recruiting94Oct 30, 2026Registry ↗
Oct 19, 2026A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysp…
NCT04419649 · Myelodysplastic Syndromes, Cytopenia
Elritercept
TAK
Takeda
Phase 2Recruiting210Oct 30, 2029Registry ↗
Oct 15, 2026A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
NCT07445087 · Hereditary Angioedema (HAE)
No intervention
TAK
Takeda
—Recruiting35Feb 29, 2032Registry ↗
Oct 15, 2026A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
NCT07250815 · Ulcerative Colitis, Crohn's Disease
No intervention
TAK
Takeda
—Withdrawn0Dec 15, 2026Registry ↗
Oct 14, 2026A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718 · Advanced or Metastatic Solid Tumors
TAK-188
TAK
Takeda
Phase 1/2Recruiting273Dec 26, 2028Registry ↗
Oct 14, 2026A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Bi…
NCT06671496 · Psoriatic Arthritis
Zasocitinib, Placebo
TAK
Takeda
Phase 3Active, not recruiting601May 18, 2027Registry ↗
Oct 13, 2026A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Mu…
NCT06980480 · Multiple Myeloma, Secondary Immunodeficiency
IGI, 10%
TAK
Takeda
Phase 3Recruiting183Sep 11, 2028Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:18 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances